Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe”In the company’s words, NCT04488419 on ClinicalTrials.gov
- Tested for
- Alzheimer Disease (3 trials), Dementia of Alzheimer Type (2 trials), Parkinson Disease Dementia, Dementia With Lewy Bodies
- Main trialPhase 2/3
- “This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.”In the company’s words, NCT04488419 on ClinicalTrials.gov
Other drugs for Alzheimer Disease
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Completed | 15 Jul 2024 | ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | |
| Phase 2/3Terminated | 23 Oct 2024 | Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | |
| Phase 2Completed | 20 May 2022 | A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease | |
| Phase 2Terminated | 19 Apr 2023 | ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026